Table 5.
Comparison between the present study and the vitamin K antagonists (VKA) dosage algorithms published for other populations.
| Algorithm | Chile (this study) |
Spain (Borobia et al., 2012) |
Germany (van Schie et al, 2011) |
CPIC (Johnson et al., 2017) |
Puerto Rico (Ramos et al., 2012) |
Brazil (Santos et al., 2015) |
Colombia (Galvez et al., 2018) |
|
|---|---|---|---|---|---|---|---|---|
| Drug | VKA | Acenocoumarol | Acenocoumarol | Acenocoumarol | Warfarin | Warfarin | Warfarin | Warfarin |
| Clinical variables | Age | X | X | X | X | X | X | X |
| Sex | X | X | X | |||||
| Initial INR | X | X | ||||||
| Amiodarone use | X | X | X | X | X | |||
| Weight | X | X | X | X | ||||
| Height | X | X | X | |||||
| Body mass index | X | X | ||||||
| CYP2C9 inducer use | X | X | X | X | X | |||
| Race/ethnicity | X | X | X | |||||
| % contribution to the final model | 19% | 22% | 23.7% | N.D | 19% | N.D | 15.9% | |
| Genetic variables | VKORC1 (rs9923231) | X | X | X | X | X | X | X |
| CYP2C9*2 (rs1799853) | X | X | X | X | X | X | X | |
| CYP2C9*3 (rs1057910) | X | X | X | X | X | X | X | |
| CYP2C9*5 (rs28371686) | African-Americans | X | ||||||
| ApoE (rs429358) | X | |||||||
| CYP4F2 (rs2108622) | X | Optional | ||||||
| % contribution to the final model | 36,9% | 39% | 52.6% | N.D | 32% | N.D | 30% | |
| Percentage of variability in VKA dosage explained | 49.99% | 60.6% | 76.3% | 47% | 51% | 40% | 45.9% | |
N.D., no data published.